Association of rs622342 SLC22A1 with the short-term changes of lipid and carbohydrate metabolism indicators in different variants of early carbohydrate metabolism disorders management in women
https://doi.org/10.21886/2219-8075-2025-16-1-39-45
Abstract
Objective: to analyze the association of rs622342 SLC22A1 with the short-term changes in fat and carbohydrate metabolism parameters in various types of early carbohydrate metabolism disorders therapy. Materials and methods: the results of management of 89 patients with excess body weight and risk factors for type 2 diabetes mellitus development were analyzed. For 3 months, 53 patients followed diet therapy, 36 patients took metformin in addition to the diet. All of the patients were genotyped for rs622342 SLC22A1. Also initially and 3 months after the beginning of therapy fasting plasma glucose, glycosylated hemoglobin, total cholesterol, low-density and high-density lipoproteins, tryglicerides were measured. Statistical processing was carried out using parametric and non-parametric criteria. Results: 3 months after the start of diet therapy, homozygous СС-carriers of the rs622342 SLC22A1 showed a significant decrease in total cholesterol and triglycerides compared with A-allele carriers. These changes were not observed when metformin was added to diet therapy. There were no significant differences in changes of fasting plasma glucose and glycated hemoglobin levels in groups with different management. Conclusions: carriers of CC rs622342 SLC22A1 are characterized with the significant decrease in total cholesterol and triglycerides levels compared to the A-allele carriers after 3 months of standard diet therapy; when metformin is added to the treatment regimen, these changes are not observed.
About the Authors
F. V. ValeevaRussian Federation
Farida V. Valeeva, Dr. Sci. (Med.), Professor, Head of Endocrinology Department
Kazan
Competing Interests:
Authors declare no conflict of interest
M. S. Medvedeva
Russian Federation
Maria S. Medvedeva, endocrinologist
Kazan
Competing Interests:
Authors declare no conflict of interest
T. A. Kiseleva
Russian Federation
Tatyana A. Kiseleva, Cand. Sci. (Med.), Associate Professor of Endocrinology Department
Kazan
Competing Interests:
Authors declare no conflict of interest
K. B. Khasanova
Russian Federation
Kamilya B. Khasanova, Cand. Sci. (Med.), Assistant of Endocrinology Department
Kazan
Competing Interests:
Authors declare no conflict of interest
R. M. Nabiullina
Russian Federation
Roza M. Nabiullina, Cand. Sci. (Med.), Associate Professor of Biochemistry and Clinical Laboratory Diagnostics Department
Kazan
Competing Interests:
Authors declare no conflict of interest
References
1. Global report on diabetes. Geneva: World Health Organization 2018. License: CC BY-NC-SA 3.0 IGO.
2. Dedov I.I., Shestakova M.V., Galstyan G.R. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-112. DOI: 10.14341/DM2004116-17
3. Barbarash O.L., Voyevoda M.I., Galstyan G.R., Shestakova M.V., Boytsov S.A., Aleksandrova O.Yu., Bryzgalina S.M., Druk I.V., Karetnikova V.N., Kashtalap V.V., Kvitkova L.V., Korennova O.Yu., Ogarkov M.Yu., Plotnikova E.Yu., Tsygankova O.V., Svarovskaya A.V., Chumakova G.A. Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology. 2019;(4):83-91. (In Russ.) DOI: 10.15829/1560-4071-2019-4-83-91
4. Grineva E.N., Mazurov V.I., Khalimov Yu.Sh., Bakulin I.G., Panov A.V., Tyrenko V.V., Novikova I.A., Babenko A.Yu., Karonova T.L., Banshikov G.T., Leboeva M.M., Lole O.Yu., Ryabova N.Yu., Toinov A.A., Semko A.A., Sheinskaya I.M. Draft resolution of the expert council of the сhief specialists of the North-West Federal District on the identification of prediabetes and the prevention of type 2 diabetes mellitus and related diseases of cardiovascular system, liver, musculoskeletal system. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2019;25(6):693-699. (In Russ.) DOI: 10.18705/1607-419X-2019-25-6-693-699
5. Dedov I., Shestakova M., Mayorov A., Mokrysheva N., Andreeva E., Bezlepkina O., Peterkova V., Artemova E., Bardiugov P., Beshlieva D., Bondarenko O., Burumkulova F., Vikulova O., Volevodz N., Galstyan G., Gomova I., Grigoryan O., Dzhemilova Z., Ibragimova L., Kalashnikov V., Kononenko I., Kuraeva T., Laptev D., Lipatov D., Melnikova O., Mikhina M., Michurova M., Motovilin O., Nikonova T., Rozhivanov R., Smirnova O., Starostina E., Surkova E., Sukhareva O., Tiselko A., Tokmakova A., Shamkhalova M., Shestakova E., Jarek-Martynowa I., Yaroslavceva M. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) DOI: 10.14341/DM13042
6. Teplova A.S., Titova V.V., Tenchurina A.I. Biochemical bases of the organoprotective properties of metformin. FOCUS. Endocrinology. 2024;5(1):59-64. (In Russ.) DOI: 10.62751/2713-0177-2024-5-1-08
7. Pozdnyakov N.O., Kagarmanyan I.N., Miroshnikov A.E., Emelyanov E.S., Gruzdeva A.A., Sirotkina A.M., Dukhanina I.A.,
8. Milkina A.A., Khokhlov A.A., Pozdnyakov S.O. Pharmacogenetic aspects oftype 2 diabetes treatment. Acta biomedica scientifica. 2020;5(3):13-23. DOI: 10.29413/ABS.2020-5.3.2.
9. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98. DOI: 10.2165/11534750-000000000-00000
10. Mato EPM, Guewo-Fokeng M, Essop MF, Owira PMO. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes. Medicine (United States). 2018;97(27). DOI: 10.1097/MD.0000000000011349
11. Reséndiz-Abarca CA, Flores-Alfaro E, Suárez-Sánchez F, Cruz M, Valladares-Salgado A, del Carmen Alarcón-Romero L, et al. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study. J Clin Pharmacol. 2019;59(10):1384–90. DOI: 10.1002/jcph.1425
12. Tkáč I, Klimčáková L, Javorský M, Fabianová M, Schroner Z, Hermanová H, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15(2):189–91. DOI: 10.1111/j.1463-1326.2012.01691.x
13. Kravtsova, O. A. (2007). Structure of the nuclear gene pool of the Volga Tatars (according to autosomal microsatellite loci). Scientific notes of Kazan University. Natural Science Series, 149(2), 138-147.
14. Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015;15(4):511–7. DOI: 10.1007/s10238-014-0322-5
15.
Review
For citations:
Valeeva F.V., Medvedeva M.S., Kiseleva T.A., Khasanova K.B., Nabiullina R.M. Association of rs622342 SLC22A1 with the short-term changes of lipid and carbohydrate metabolism indicators in different variants of early carbohydrate metabolism disorders management in women. Medical Herald of the South of Russia. 2025;16(1):39-45. (In Russ.) https://doi.org/10.21886/2219-8075-2025-16-1-39-45